The Company is a Korea-based company engaged in the manufacture and sale of precision diagnostic products. The Company s main products include BRCAaccuTest products used for hereditary breast and ovarian cancer testing, HEMEaccuTest products that tests the causative genes related to blood cancer such as leukemia, lymphoma, and bone marrow cancer, SOLIDaccuTest products that test the causative genes of solid cancer tissues such as lung cancer, colon cancer and stomach cancer. In addition, the Company manufactures and sells products of HLAaccuTest products that tests tissue-specific antigens used for bone marrow transplantation, ONCOaccuPanel products for precise diagnosis of large-capacity solid cancer, HEREDaccuTest products for precise diagnosis for rare diseases. The Company also provides services such as genetic testing direct to customer(DTC) and personalized healthcare. The Company was established on October 30, 2015. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 10, 2020.
Headquarters
303-307, 314Ho, 288, Digital-Ro, Guro-Gu
Seoul; Seoul;
Contact Details: Purchase the Ngenebio Co., Ltd. report to view the information.
Website: http://ngenebio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service